Seguici sui social:

CDK 4/6 INHIBITORS– EVOLUTION OF THE PARADIGM - Fad asincrona Accreditata dal 14.03.2022 al 14.06.2022

  • 14 Mar 2022 - 14 Jun 2022
Numero crediti assegnati4
Categorie con ECM Medico Chirurgo (Anatomia patologica, Chirurgia generale, Ginecologia e ostetricia, Oncologia, Radioterapia), Infermiere
Numero provider256
Presidente del congressoProf. Giovanni Scambia (Direttore della Scuola Class)
Segreteria ScientificaDott.ssa Ida Paris (Responsabile scientifico)
Segreteria organizzativaMolipharma srl

Agli iscritti al webinar del 07 marzo verrĂ  fornito anche l'accesso alla FAD asincrona accreditata attiva dal 14 marzo al 14 giugno 2022.


CDK4 and CDK6 are cyclin-dependent kinases that control the transition between the G1 and S phases of the cell cycle. CDK4/6 activity is typically deregulated and overactive in cancer cells. There can be amplification or overex-pression of the genes encoding cyclins or of the genes encoding the CDKs themselves. Additionally, loss of endoge-nous INK4 inhibitors, by gene deletion, mutation, or promoter hypermethylation, can also lead to overactivity of CDK4 and CDK6. A major target of CDK4 and CDK6 during cell-cycle progression is the retinoblastoma protein (Rb). When Rb is phosphorylated, its growth-suppressive properties are inactivated. Selective CDK4/6 inhibitors “turn off” these kinases and dephosphorylate Rb, resulting in a block of cell-cycle progression in mid-G1. This causes cell-cycle arrest and prevents the proliferation of cancer cells. Although the initial response to a selective CDK4/6 inhibi-tor is typically cell-cycle arrest, in some cases arrested cells enter a state of senescence. Understanding the deter-minants of whether a cell undergoes reversible G1 arrest or enters a senescent state is an important research area. CDK4/6 inhibitors may produce the greatest clinical benefit. To date, estrogen receptor–positive breast cancer is the malignancy for which this class of drugs has proven most effective and for which we have the most mature data from randomized trials comparing these drugs with endocrine therapy alone.

This meeting would like to review the mechanisms of action and efficacy of these drugs in order to evidence the best choice in clinical management of metastatic estrogen receptor–positive breast cancer with special point of view in their future development in every setting.